Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129575 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TP53CYP3A4CD44MAPT | |
| SCHEMBL2734347 | 0.82 | ALDH1A1 (0.32) | ALDH1A1TP53MAPTNPC1RAB9A | |
| SCHEMBL14433298 | 0.78 | GAA (0.32) | ALDH1A1MEN1KMT2A | |
| SCHEMBL11595680 | 0.75 | ALDH1A1 (0.40) | ALDH1A1TP53MAPTKDM4EMEN1 | |
| SCHEMBL13823607 | 0.75 | GAA (0.42) | ALDH1A1KDM4EMEN1POLBHPGD | |
| SCHEMBL13613581 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MAPTKDM4EMEN1POLB | |
| SCHEMBL1964815 | 0.74 | APLNR (0.35) | ALDH1A1TP53CYP3A4MAPTHPGD | |
| SCHEMBL13893141 | 0.70 | CD44 (0.38) | ALDH1A1CYP3A4CD44MAPTKDM4E | |
| SCHEMBL14037418 | 0.69 | MAPT (0.40) | ALDH1A1TP53CYP3A4MAPTKDM4E | |
| SCHEMBL10348095 | 0.68 | CD44 (0.48) | ALDH1A1CYP3A4CD44MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| EP-1885704-B1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| EP-1569896-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005040100-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040119-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1506167-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2005002551-A2 | VANILLOID RECEPTOR (VR) 1 INHIBITORS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV)-MEDIATED PAIN STATES | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | WO | disclosed |
| EP-1493438-A1 | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states | Bayer HealthCare AG (DE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004072020-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004052845-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052846-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003095420-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | OPRL1, OPRK1, VAT1 | ALDH1A1 541/4885TP53 1908/4885CYP3A4 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.